333 related articles for article (PubMed ID: 31227504)
1. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
Somaiah N; Block MS; Kim JW; Shapiro GI; Do KT; Hwu P; Eder JP; Jones RL; Lu H; Ter Meulen JH; Bohac C; Chen M; Hsu FJ; Gnjatic S; Pollack SM
Clin Cancer Res; 2019 Oct; 25(19):5808-5817. PubMed ID: 31227504
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
[TBL] [Abstract][Full Text] [Related]
4. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
5. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
6. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.
Albershardt TC; Campbell DJ; Parsons AJ; Slough MM; Ter Meulen J; Berglund P
Mol Ther Oncolytics; 2016; 3():16010. PubMed ID: 27626061
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
10. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
Bender A; Karbach J; Neumann A; Jäger D; Al-Batran SE; Atmaca A; Weidmann E; Biskamp M; Gnjatic S; Pan L; Hoffman E; Old LJ; Knuth A; Jäger E
Cancer Immun; 2007 Oct; 7():16. PubMed ID: 17944437
[TBL] [Abstract][Full Text] [Related]
11. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.
Palmowski MJ; Lopes L; Ikeda Y; Salio M; Cerundolo V; Collins MK
J Immunol; 2004 Feb; 172(3):1582-7. PubMed ID: 14734738
[TBL] [Abstract][Full Text] [Related]
12. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
13. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
14. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
Lopes L; Fletcher K; Ikeda Y; Collins M
Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
[TBL] [Abstract][Full Text] [Related]
18. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
